Vancomycin use and cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation
Shijia Zhang, Ryan Shanley, Daniel J. Weisdorf, Armin Rashidi
Abstract
Key Points Vancomycin exposure in the pre-engraftment period was associated with an increased risk for CMV reactivation after allogeneic HCT. Some gram-positive bacteria may protect against CMV reactivation.
Topics & Concepts
CytomegalovirusVancomycinHematopoietic cellTransplantationHematopoietic stem cell transplantationImmunologyHaematopoiesisMedicineCytomegalovirus infectionsVirologyHuman cytomegalovirusBiologyBacteriaHuman immunodeficiency virus (HIV)Stem cellViral diseaseVirusInternal medicineHerpesviridaeStaphylococcus aureusGeneticsCytomegalovirus and herpesvirus researchHerpesvirus Infections and TreatmentsHematopoietic Stem Cell Transplantation